Regulation of ubiquitin transfer by XIAP, a dimeric RING E3 ligase

Biochemical Journal

Volumn 450, Issue 3, 2013, Pages 629-638

  Nakatani, Yoshio ^a   Kleffmann, Torsten ^a   Linke, Katrin ^a   Condon, Stephen M ^b   Hinds, Mark G ^c,d   Day, Catherine L ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b TetraLogic Pharmaceuticals   (United States)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cross linking coupled with mass spectrometry analysis; Inhibitor of apoptosis (IAP); RING; Ubiquitin; X linked inhibitor of apoptosis (XIAP)

Indexed keywords

UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CHEMICAL ANALYSIS; DIMERIZATION; ENZYME ACTIVITY; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; PROTEIN TRANSPORT; RING FINGER MOTIF;

AMINO ACID SEQUENCE; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PHENYLALANINE; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; SUBSTRATE SPECIFICITY; UBIQUITIN; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84874590707     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20121702     Document Type: Article

References (49)

1. Deshaies, R. J. and Joazeiro, C. A. (2009) RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399-434
2. Budhidarmo, R., Nakatani, Y. and Day, C. L. (2012) RINGs hold the key to ubiquitin transfer. Trends Biol. Sci. 37, 58-65
3. Mace, P. D., Linke, K., Feltham, R., Schumacher, F. R., Smith, C. A., Vaux, D. L., Silke, J. and Day, C. L. (2008) Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment. J. Biol. Chem. 283, 31633-31640
4. Bentley, M. L., Corn, J. E., Dong, K. C., Phung, Q., Cheung, T. K. and Cochran, A. G. (2011) Recognition of UbcH5c and the nucleosome by the Bmi1-Ring1b ubiquitin ligase complex. EMBO J. 30, 3285-3297
5. Zhang, L., Fairall, L., Goult, B. T., Calkin, A. C., Hong, C., Millard, C. J., Tontonoz, P. and Schwabe, J. W. (2011) The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes Dev. 25, 1262-1274
6. Huang, A., Dejong, R., Wienk, H., Winkler, G., Timmers, H. and Boelens, R. (2009) E2-c-Cbl recognition is necessary but not sufficient for ubiquitination activity. J. Mol. Biol. 385, 507-519
7. Zheng, N., Wang, P., Jeffrey, P. D. and Pavletich, N. P. (2000) Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102, 533-539
8. Plechanovova, A., Jaffray, E. G., McMahon, S. A., Johnson, K. A., Navrátilová, I., Naismith, J. H. and Hay, R. T. (2011) Mechanism of ubiquitylation by dimeric RING ligase RNF4. Nat. Struct. Mol. Biol. 18, 1052-1059
9. Pruneda, J. N., Littlefield, P. J., Soss, S. E., Nordquist, K. A., Chazin, W. J., Brzovic, P. S. and Klevit, R. E. (2012) Structure of an E3:E2-Ub complex reveals an allosteric mechanism shared among RING/U-box ligases. Mol. Cell 47, 933-942
10. Spratt, D. E., Wu, K., Kovacev, J., Pan, Z. Q. and Shaw, G. S. (2012) Selective recruitment of an E2 ubiquitin complex by an E3 ubiquitin ligase. J. Biol. Chem. 287, 17374-17385
11. Plechanovova, A., Jaffray, E. G., Tatham, M. H., Naismith, J. H. and Hay, R. T. (2012) Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. Nature 489, 115-120
12. Dou, H., Buetow, L., Sibbet, G. J., Cameron, K. and Huang, D. T. (2012) BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer. Nat. Struct. Mol. Biol. 19, 876-883
13. Vaux, D. L. and Silke, J. (2005) IAPs, RINGs and ubiquitylation. Nat. Rev. Mol. Cell Biol. 6, 287-297
14. Feltham, R., Bettjeman, B., Budhidarmo, R., Mace, P. D., Shirley, S., Condon, S. M., Chunduru, S. K., McKinlay, M. A., Vaux, D. L., Silke, J. and Day, C. L. (2011) Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J. Biol. Chem. 286, 17015-17028
15. Dueber, E. C., Schoeffler, A. J., Lingel, A., Elliott, J. M., Fedorova, A. V., Giannetti, A. M., Zobel, K., Maurer, B., Varfolomeev, E., Wu, P. et al. (2011) Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334, 376-380
16. Sun, H., Nikolovska-Coleska, Z., Yang, C. Y., Xu, L., Tomita, Y., Krajewski, K., Roller, P. P. and Wang, S. (2004) Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J. Med. Chem. 47, 4147-4150
17. Mannhold, R., Fulda, S. and Carosati, E. (2010) IAP antagonists: promising candidates for cancer therapy. Drug Discovery Today 15, 210-219
18. Vince, J. E., Wong, W. W., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M. et al. (2007) IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682-693
19. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. et al. (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669-681
20. Fulda, S. and Vucic, D. (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discovery 11, 109-124
21. Varfolomeev, E., Moradi, E., Dynek, J. N., Zha, J., Fedorova, A. V., Deshayes, K., Fairbrother, W. J., Newton, K., Le Couter, J. and Vucic, D. (2012) Characterization of ML-IAP protein stability and physiological role in vivo. Biochem. J. 447, 427-436
22. Eckelman, B. P., Salvesen, G. S. and Scott, F. L. (2006) Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 7, 988-994
23. Damgaard, R. B., Nachbur, U., Yabal, M., Wong, W. W.-L., Fiil, B. K., Kastirr, M., Rieser, E., Rickard, J. A., Bankovacki, A., Peschel, C. et al. (2012) The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol. Cell 46, 746-758
24. Oberoi, T. K., Dogan, T., Hocking, J. C., Scholz, R.-P., Mooz, J., Anderson, C. L., Karreman, C., Heringdorf, D. M. Z., Schmidt, G., Ruonala, M. et al. (2011) IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. EMBO J. 31, 14-28
25. Liu, H. and Naismith, J. H. (2008) An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnol. 8, 91
26. Sato, Y., Yoshikawa, A., Yamagata, A., Mimura, H., Yamashita, M., Ookata, K., Nureki, O., Iwai, K., Komada, M. and Fukai, S. (2008) Structural basis for specific cleavage of Lys63-linked polyubiquitin chains. Nature 455, 358-362
27. Serniwka, S. A. and Shaw, G. S. (2009) The structure of the UbcH8-ubiquitin complex shows a unique ubiquitin interaction site. Biochemistry 48, 12169-12179
28. Merkley, N. (2005) Ubiquitin manipulation by an E2 conjugating enzyme using a novel covalent intermediate. J. Biol. Chem. 280, 31732-31738
29. Panchaud, A., Singh, P., Shaffer, S. A. and Goodlett, D. R. (2010) xComb: a cross-linked peptide database approach to protein-protein interaction analysis. J. Proteome Res. 9, 2508-2515
30. Hamilton, K., Ellison, M., Barber, K., Williams, R., Huzil, J., McKenna, S., Ptak, C., Glover, M. and Shaw, G. (2001) Structure of a conjugating enzyme-ubiquitin thiolester intermediate reveals a novel role for the ubiquitin tail. Structure 9, 897-904
31. Komander, D. and Rape, M. (2012) The ubiquitin code. Annu. Rev. Biochem. 81, 203-229
32. Gyrd-Hansen, M., Darding, M., Miasari, M., Santoro, M., Zender, L., Xue, W., Tenev, T., da Fonseca, P. C., Zvelebil, M., Bujnicki, J. et al. (2008) IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis. Nat. Cell Biol. 10, 1309-1317
33. Brandl, M., Weiss, M. S., Jabs, A., Suhnel, J. and Hilgenfeld, R. (2001) C-H. .. pi-interactions in proteins. J. Mol. Biol. 307, 357-377
34. Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J. and Day, C. L. (2008) Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 15, 841-848
35. Dolezelova, P., Cetkovska, K., Vousden, K. H. and Uldrijan, S. (2012) Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers. Cell Cycle 11, 953-962
36. Uldrijan, S., Pannekoek, W. J. and Vousden, K. H. (2007) An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 26, 102-112
37. Iyappan, S., Wollscheid, H. P., Rojas-Fernandez, A., Marquardt, A., Tang, H. C., Singh, R. K. and Scheffner, M. (2010) Turning the RING domain protein MdmX into an active ubiquitin-protein ligase. J. Biol. Chem. 285, 33065-33072
38. Mattiroli, F., Vissers, J. H., van Dijk, W. J., Ikpa, P., Citterio, E., Vermeulen, W., Marteijn, J. A. and Sixma, T. K. (2012) RNF168 ubiquitinates K13-15 on H2A/H2AX to drive DNA damage signaling. Cell 150, 1182-1195
39. Huang, A., Hibbert, R. G., de Jong, R. N., Das, D., Sixma, T. K. and Boelens, R. (2011) Symmetry and asymmetry of the RING-RING dimer of Rad18. J. Mol. Biol. 410, 424-435
40. Brzovic, P. S., Meza, J. E., King, M. C. and Klevit, R. E. (2001) BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J. Biol. Chem. 276, 41399-41406
41. Vander Kooi, C. W., Ohi, M. D., Rosenberg, J. A., Oldham, M. L., Newcomer, M. E., Gould, K. L. and Chazin, W. J. (2006) The Prp19 U-box crystal structure suggests a common dimeric architecture for a class of oligomeric E3 ubiquitin ligases. Biochemistry 45, 121-130
42. Gareau, J. R., Reverter, D. and Lima, C. D. (2012) Determinants of small ubiquitin-like modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 binding activities of nucleoporin RanBP2. J. Biol. Chem. 287, 4740-4751
43. Lu, M., Lin, S. C., Huang, Y., Kang, Y. J., Rich, R., Lo, Y. C., Myszka, D., Han, J. and Wu, H. (2007) XIAP induces NF-κB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol. Cell 26, 689-702
44. Tse, M. K., Cho, C. K., Wong, W. F., Zou, B., Hui, S. K., Wong, B. C. and Sze, K. H. (2012) Domain organization of XAF1 and the identification and characterization of XIAP(RING)-binding domain of XAF1. Protein Sci. 21, 1418-1428
45. Duda, D. M., Olszewski, J. L., Tron, A. E., Hammel, M., Lambert, L. J., Waddell, M. B., Mittag, T., DeCaprio, J. A. and Schulman, B. A. (2012) Structure of a glomulin-RBX1-CUL1 complex: inhibition of a RING E3 ligase through masking of its E2-binding surface. Mol. Cell 47, 371-382
46. Nakhaei, P., Sun, Q., Solis, M., Mesplede, T., Bonneil, E., Paz, S., Lin, R. and Hiscott, J. (2011) IκB kinase epsilon-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis. J. Virol. 86, 726-737
47. Schimmer, A. D., Dalili, S., Batey, R. A. and Riedl, S. J. (2006) Targeting XIAP for the treatment of malignancy. Cell Death Differ. 13, 179-188
48. Dynek, J. N. and Vucic, D. (2010) Antagonists of IAP proteins as cancer therapeutics. Cancer Lett., doi:10.1016/j.canlet.2010.06.013
49. Krieg, A., Correa, R. G., Garrison, J. B., Le Negrate, G., Welsh, K., Huang, Z., Knoefel, W. T. and Reed, J. C. (2009) XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl. Acad. Sci. U.S.A. 106, 14524-14529